Fate Therapeutics, Inc. (NASDAQ:FATE), featuring a year-to-date gain of 102.04% and upside potential of 228.30%, secures a spot on our list of hot biotech stocks under $5 to buy.
Fresh Phase 1 data presented at a major rheumatology conference gave analysts fresh reason to stay constructive on Fate Therapeutics, Inc. (NASDAQ:FATE)’s lead off-the-shelf cell therapy program.
On June 8, 2026, H.C. Wainwright reiterated a “Buy” rating and $7.00 price target on Fate Therapeutics following updated Phase 1 data presented at the annual EULAR meeting for FT819, its iPSC-derived, off-the-shelf CD19 CAR-T therapy.
The data covered 16 heavily pretreated systemic lupus erythematosus patients with a median disease duration of 7.6 years, seven median prior treatments, and a mean baseline SLEDAI-2K score of 13.6. FT819 with bendamustine conditioning in seven patients produced deeper and more consistent B-cell depletion and greater FT819 expansion compared to cyclophosphamide conditioning in six patients. B-cell receptor sequencing showed a 74% to 96% reduction in the top 50 most expanded clones at baseline across all five patients analyzed, with dominant clones not reappearing at any time point up to 12 months.
No patients experienced Grade 3 or higher cytokine release syndrome, supporting the potential for outpatient administration. FT819 with less-intensive conditioning showed early and sustained clinical improvement, with a trend toward more favorable responses with bendamustine conditioning.
H.C. Wainwright said the results support the potentially registrational Phase 2 RECLAIM-LN trial, which evaluates FT819 with bendamustine conditioning in patients with refractory moderate-to-severe SLE with lupus nephritis. The firm expects additional clinical, regulatory, and operational updates for FT819 in the second half of 2026, Investing.com reported.
Fate Therapeutics, Inc. (NASDAQ:FATE) is a California-based clinical-stage biopharmaceutical company that focuses on the development of programmed cellular immunotherapies for people living with cancer and immune disorders.
While we acknowledge the risk and potential of FATE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than FATE and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
